
Record of Telephone Conversation, February 11, 2013 - Q-Pan

 

Submission Type: BLA


Submission ID: 125419/0


Office: OVRR


 Product:
 Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

Applicant:
 ID Biomedical Corporation of Quebec (dba GlaxoSmithKline Biologicals)

Telecon Date/Time: 11-Feb-2013 12:31 PM Initiated by FDA? No

Telephone Number: 610-787-3435

Communication Categorie(s):
 1. Other - GSK response to CBER comments of Feb. 8, 2013

Author: CARMEN COLLAZO-CUSTODIO

Telecon Summary:
 GSK decided to remove the information submitted in the BLA regarding the use of –b(4)--------------------- for storage of the –b(4)------------- in response to CBER’s comments provided on February 8, 2013. Due to GSK’s decision, a conference call scheduled for February 8, 2013, at 2:00 PM was cancelled since the matter was resolved and there was no need for further discussion.

FDA Participants: Carmen Collazo-Custodio

Non-FDA Participants: Michael Schwartz


From: Michael Schwartz [mailto:michael.p.schwartz@gsk.com] 
Sent: Monday, February 11, 2013 12:31 PM
To: Collazo, Carmen
Subject: --b(4)---------- - withdraw from BLA 

Dear Carmen,

Due to the CBER comments and concerns with the use of –b(4)-------------for storage of -b(4) we have decided to withdraw their use from the BLA.
•--b(4)---- has discontinued the—b(4)-------
•GSK does not plan to use these –b(4)---- in the future (since –b(4)---- has discontinued them)
•Only a small amount of ----b(4)-------------) is stored in –b(4)------------- as part of the stockpile
•The small amount in –b(4)------- is approaching –b(4)------- of age (late 2013), expiry

If GSK chooses to pursue the use of this small volume of –b(4) in the stockpile we will submit for licensure of the –b(4)------- as a post approval submission.

Kind Regards,

Mike

Michael P. Schwartz, PhD
 U.S. Regulatory Affairs - Adjuvanted Influenza Vaccines
 610-787-3435
